Johnson Financial Group Inc. Reduces Holdings in Veeva Systems Inc. $VEEV

Johnson Financial Group Inc. reduced its position in Veeva Systems Inc. (NYSE:VEEV) by 69.0% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 231 shares of the technology company’s stock after selling 515 shares during the period. Johnson Financial Group Inc.’s holdings in Veeva Systems were worth $67,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Sigma Planning Corp lifted its stake in Veeva Systems by 1.2% in the second quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock valued at $958,000 after buying an additional 39 shares during the last quarter. Keybank National Association OH increased its holdings in shares of Veeva Systems by 1.4% in the 2nd quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock valued at $889,000 after acquiring an additional 42 shares during the period. Facet Wealth Inc. increased its holdings in shares of Veeva Systems by 3.3% in the 2nd quarter. Facet Wealth Inc. now owns 1,342 shares of the technology company’s stock valued at $381,000 after acquiring an additional 43 shares during the period. TFB Advisors LLC raised its position in Veeva Systems by 1.2% in the 1st quarter. TFB Advisors LLC now owns 3,586 shares of the technology company’s stock valued at $831,000 after purchasing an additional 44 shares during the last quarter. Finally, Triangle Securities Wealth Management boosted its stake in Veeva Systems by 0.8% during the 2nd quarter. Triangle Securities Wealth Management now owns 5,782 shares of the technology company’s stock worth $1,665,000 after purchasing an additional 45 shares during the period. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Insider Buying and Selling at Veeva Systems

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. The trade was a 19.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jonathan Faddis sold 720 shares of the company’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares in the company, valued at approximately $2,345,608.16. This trade represents a 8.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 24,665 shares of company stock valued at $7,438,000. 10.30% of the stock is owned by company insiders.

Veeva Systems Stock Down 0.2%

Shares of NYSE:VEEV opened at $240.30 on Friday. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The company has a 50-day moving average price of $284.10 and a 200 day moving average price of $278.85. The company has a market cap of $39.39 billion, a P/E ratio of 49.34, a PEG ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The business had revenue of $811.24 million during the quarter, compared to the consensus estimate of $792.37 million. During the same period in the prior year, the business posted $1.75 EPS. The company’s revenue for the quarter was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS. Q4 2026 guidance at 1.920-1.920 EPS. Analysts expect that Veeva Systems Inc. will post 4.35 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on VEEV. Truist Financial lifted their price objective on shares of Veeva Systems from $268.00 to $275.00 and gave the company a “hold” rating in a research note on Thursday, August 28th. Oppenheimer restated an “outperform” rating and issued a $325.00 price target on shares of Veeva Systems in a research report on Thursday, August 28th. Robert W. Baird upped their price objective on Veeva Systems from $314.00 to $319.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Weiss Ratings raised Veeva Systems from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, November 24th. Finally, Mizuho boosted their target price on Veeva Systems from $295.00 to $325.00 and gave the company an “outperform” rating in a report on Friday, August 29th. Twenty research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average target price of $305.88.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.